Osteoporosis and chronic kidney disease

Seminars in Dialysis

Volumn 20, Issue 5, 2007, Pages 423-430

  Gal Moscovici, Anca ^b   Sprague, Stuart M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE DENSITY; CHRONIC KIDNEY FAILURE; HEALTH; HUMAN; METABOLISM; MORBIDITY; OSTEOPOROSIS; PROGNOSIS; RISK FACTOR;

BONE DENSITY; HUMANS; KIDNEY FAILURE, CHRONIC; MORBIDITY; OSTEOPOROSIS; PROGNOSIS; RISK FACTORS; WORLD HEALTH;

EID: 34748859259     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00319.x     Document Type: Article

References (95)

1. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. : Bone density at various sites for prediction of hip fractures. Lancet 341 : 72 75, 1993
2. Melton III. LJ, Kan SH, Wahner HW, Riggs BL : Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age. J Clin Epidemiol 41 : 985 994, 1988
3. Melton III. LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL : Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8 : 1227 1233, 1993
4. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G : Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945 1953, 2006
5. Llach F, Bover J : Renal osteodystrophy. In : Brenner BM (ed). The Kidney. Philadelphia : WB Saunders, 1996 : 2187 2273
6. Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, Ball A, Weiss NS : Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58 (5 2200 2205, 2000
7. Coco M, Rush H : Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36 (6 1115 1121, 2000
8. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T : Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33 (2 287 293, 1999
9. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H : Vascular calcification and osteoporosis-from clinical observation towards molecular understanding. Osteoporos Int 251 259, 2006 Dec 7 GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 : 2208 2218, 2004
10. Quarles LD : FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 285 : E1 E9, 2003
11. Ritz E, Gross ML : Hyperphosphatemia in renal failure. Blood Purif 23 : 6 9, 2005
12. Santos FR, Moyses RM, Montenegro FL, Jorgetti V, Noronha IL : IL-1beta, TNF-alpha, TGF-beta, and bFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int 63 (3 899 907, 2003
13. Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K : Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. J Cell Physiol 196 : 180 189, 2003
14. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB : Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinolog 145 : 3087 3094, 2004
15. Panda DK, Miao D, Bolivar I, Li J, Huo R, Hendy GN, Goltzman D : Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 279 (16 16754 16766, 2004
16. Zaidi M, Adebanjo OA, Moonga BS, Sun L, Huang CL : Emerging insights into the role of calcium ions in osteoclast regulation. J Bone Miner Res 14 : 669 674, 1999
17. Zaidi M, Moonga BS, Adebanjo OA : Novel mechanisms of calcium handling by the osteoclast: A review- hypothesis. Proc Assoc Am Physicians 111 : 319 327, 1999
18. Lorget F, Kamel S, Mentaverri R, Wattel A, Naassila M, Maamer M, Brazier M : High extracellular calcium concentrations directly stimulate osteoclast apoptosis. Biochem Biophys Res Commun 268 : 899 903, 2000
19. Kanatani M, Sugimoto T, Kanzawa M, Yano S, Chihara K : High extracellular calcium inhibits osteoclast-like cell formation by directly acting on the calcium-sensing receptor existing in osteoclast precursor cells. Biochem Biophys Res Commun 261 : 144 148, 1999
20. Xu J, Wang C, Han R, Pavlos N, Phan T, Steer JH, Bakker AJ, Joyce DA, Zheng MH : Evidence of reciprocal regulation between the high extracellular calcium and RANKL signal transduction pathways in RAW cell derived osteoclasts. J Cell Physiol 202 : 554 562, 2005
21. Eastwood JB : Quantitative bone histology in 38 patients with advanced renal failure. J Clin Pathol 35 : 125 134, 1982
22. Mora Palma FJ, Ellis HA, Cook DB, Dewar JH, Ward MK, Wilkinson R, Kerr DN : Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med 52 : 332 348, 1983
23. Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, Bonucci E, Taggi F : Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant 11 : 813 819, 1996
24. Dahl E, Nordal KP, Attramadal A, Halse J, Flatmark A : Renal osteodystrophy in predialysis patients without stainable bone aluminum. A cross-sectional bone-histomorphometric study. Acta Med Scand 224 : 157 164, 1988
25. Hernandez D, Concepcion MT, Lorenzo V, Martinez ME, Rodriguez A, De Bonis E, Gonzalez-Posada JM, Felsenfeld AJ, Rodriguez M, Torres A : Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 9 : 517 523, 1994
26. Shin SK, Kim DH, Kim HS, Shin KT, Ma KA, Kim SJ, Kwak YS, Ha SK, Sherrard DJ : Renal osteodystrophy in pre-dialysis patients: ethnic difference? Perit Dial Int 19 (Suppl. 2 S402 S407, 1999
27. Spasovski GB, Bervoets AR, Behets GJ, Ivanovski N, Sikole A, Dams G, Couttenye MM, De Broe ME, D'Haese PC : Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant 18 : 1159 1166, 2003
28. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, Hernandez A, de Bonis E, Darias E, Gonzalez-Posada JM, et al. : Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 47 : 1434 1442, 1995
29. Malluche HH : Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant 17 (Suppl. 2 21 24, 2002
30. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV : The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 43 : 436 442, 1993
31. Malluche HH, Mawad H, Monier-Faugere MC : The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? Nephrol Dial Transplant 19 (Suppl. 1 i9 i13, 2004
32. Ginaldi L, Di Benedetto MC, De Martinis M : Osteoporosis, inflammation and ageing. Immun Ageing 2 : 14, 2005
33. Delmas PD : Treatment of postmenopausal osteoporosis. Lancet 359 : 2018 2026, 2002
34. Yun AJ, Lee PY : Maladaptation of the link between inflammation and bone turnover may be a key determinant of osteoporosis. Med Hypotheses 63 : 532 537, 2004
35. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R : Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA 100 : 9090 9095, 2003
36. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Seibel MJ, Ziegler R, Pfeilschifter J : Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade post menopause. J Clin Endocrinol Metab 86 : 2032 2042, 2001
37. Bruunsgaard H : Effects of tumor necrosis factor-alpha and interleukin-6 in elderly populations. Eur Cytokine Netw 13 : 389 391, 2002
38. Abrahamsen B, Bendtzen K, Beck-Nielsen H : Cytokines and T-lymphocyte subsets in healthy post-menopausal women: estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. Bone 20 : 251 258, 1997
39. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, Pacifici R : Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A 98 (24 13960 13965, 2001
40. Barreto FC, Barreto DV, Moyses RM, Neves CL, Jorgetti V, Draibe SA, Canziani ME, Carvalho AB : Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int 69 : 1852 1857, 2006
41. Gal-Moscovici A, Gal M, Popovtzer MM, Foldes AJ, Scherzer P : Bone turnover in experimental menopause: impact on superimposed chronic kidney disease (CKD). J Am Soc Nephrol Oct 16 : 739A, 2005 JS, Moe SM : Osteoporosis in end-state renal disease. Semin Nephrol 19 (2 115 122, 1999 Review
42. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C : Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58 (1 396 399, 2000
43. Holley JL, Schmidt RJ : Hormone replacement therapy in postmenopausal women with end-stage renal disease: a review of the issues. Semin Dial 14 (3 146 149, 2001 Review
44. Ensrud KE, Lui L-Y, Taylor BC, Ishani A, Shlipak MG, Stone KL, Cauley JA, Jamal SA, Antoniucci DM, Cummings SR : Renal function and risk of hip and vertebral fractures among older women. Arch Int Med 167 : 133 139, 2007
45. WHO Study Group (1994) : Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva : Switzerland, 1994
46. Seeman E, Delmas PD : Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 354 (21 2250 2261, 2006 Review
47. Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J : Osteoporosis Work Group. Osteoporosis in chronic kidney disease. Am J Kidney Dis 43 (3 566 571, 2004 Review
48. Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G : Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 54 (3 218 226, 2000
49. Urena P, Bernard-Poenaru O, Ostertag A, Baudoin C, Cohen-Solal M, Cantor T, De Vernejoul MC : Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 18 (11 2325 2331, 2003
50. Negri AL, Barone R, Quiroga MA, Bravo M, Marino A, Fradinger E, Bogado CE, Zanchetta JR : Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Perit Dial Int 24 (2 163 168, 2004
51. DeVita MV, Rasenas LL, Bansal M, Gleim GW, Zabetakis PM, Gardenswartz MH, Michelis MF : Assessment of renal osteodystrophy in hemodialysis patients. Medicine (Baltimore) 71 (5 284 290, 1992
52. Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A : Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 13 (6 437 443, 2000
53. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K : Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56 (3 1084 1093, 1999
54. Klawansky S, Komaroff E, Cavanaugh Jr. PF, Mitchell DY, Gordon MJ, Connelly JE, Ross SD : Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14 (7 570 576, 2003 Epub 2003 Jul 3
55. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH : Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46 : 855 861, 1994
56. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, De Vernejoul MC : Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15 : 1943 1951, 2004
57. Block GA, Port FK : Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35 : 1226 1237, 2000
58. Andress DL : Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 69 (1 33 43, 2006 Review
59. Raggi P, Boulay A, Chasin-Taber S, Amin D, Dillon M, Burke SK, Chertow GM : Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39 : 695 701, 2002
60. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H : Arterial medial calcification in end-stage renal disease: impact on all cause and cardiovascular mortality. Nephrol Dial Transplant 18 : 1731 1740, 2003
61. Yildiz A, Memisoglu E, Oflaz H, Yazici H, Pusuroglu H, Akkaya V, Erzengin F, Tepe S : Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic hemodialysis patients. Nephrol Dial Transplant 20 : 760 767, 2005
62. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V : Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89 : 4246 4253, 2004
63. Bagger YZ, Tanko LB, Alexandersen P, Qin G, Christiansen C : Prospective Epidemiological Risk Factors Study Group Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med 259 : 598 605, 2006
64. Tanko LB, Bagger YZ : Christiansen C Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 73 : 15 20, 2003
65. Demer LL : Vascular calcification and osteoporosis:inflammatory responses to oxidized lipids. Int J Epidemiol 31 : 737 741, 2002
66. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL : Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96 : 1755 1760, 1997
67. Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y, Berliner JA, Demer LL : Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 17 : 680 687, 1997
68. Jie KG, Bots ML, Vermeer C, Witteman JC, Grobbee DE : Vitamin K status and bone mass in women with and without aortic atherosclerosis: a population-based study. Calcif Tissue Int 59 : 352 356, 1996
69. Kawano K, Ogata N, Chiano M, Molloy H, Kleyn P, Spector TD, Uchida M, Hosoi T, Suzuki T, Orimo H, Inoue S, Nabeshima Y, Nakamura K, Kuro-o M, Kawaguchi H : Klotho gene polymorphisms associated with bone density of aged postmenopausal women. J Bone Miner Res 17 : 1744 1751, 2002
70. Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF : Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res 17 : 1245 1255, 2002
71. Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, Hofbauer LC, Schaefer JR : Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 89 : 3764 3768, 2004
72. Osawa M, Tian W, Horiuchi H, Kaneko M, Umetsu K : Association of alpha2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Gene 116 : 146 151, 2005
73. Diaz-Corte C, Fernandez-Martin LJ, Barreto S, et al. : Effect of aluminum load on parathyroid hormone synthesis. Nephrol Dial Transplant 16 : 742 745, 2001
74. Nordal KP : Calcium carbonate versus aluminum hydroxide as phosphate binder in hemodialysis patients. A randomized prospective study. Kidney Int 49 : 926, 1996
75. Locatelli F, Cannata-Andia JB, Drueke TB, Horl WH, Fouque D, Heimburger O, Ritz E : Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 17 (5 723 731, 2002
76. Salusky IB, Goodman WG : Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 12 (9 1978 1985, 2001 Review
77. Salusky IB, Kuizon BD, Belin TR, Ramirez JA, Gales B, Segre GV, Goodman WG : Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 54 (3 907 914, 1998
78. Chertow GM, Burke SK, Raggi P : Treat to goal working group: sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 : 245 252, 2002
79. D'Haese PC, Spasowski GB, Sikole A, et al. : A multicenter study on the effect of lanthanum carbonate (Forsenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 63 (Suppl. 65 S73 S78, 2003
80. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E : A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 30 (1 105 112, 1997
81. Slatopolsky E, Finch J, Ritter C, Denda M, Morrissey J, Brown A, DeLuca H : A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26 (5 852 860, 1995
82. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D : Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63 : 1483 1490, 2003
83. Slatopolsky E, Cozzolino M, Lu Y, Finch J, Dusso A, Staniforth M, Wein Y, Webster J : Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney Int 63 (6 2020 2027, 2003
84. Jokihaara J, Porsti I, Pajamaki I, Vuohelainen T, Jolma P, Koobi P, Kalliovalkama J, Niemela O, Kannus P, Sievanen H, Jarvinen TL : Paricalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease. J Bone Miner Res 21 (5 745 751, 2006
85. Teng M, Wolf M, Lowrie E, Ofshun N, Lazarus JM, Thadhani R : Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349 : 446 456, 2003
86. Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM : Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 19 (5 1174 1181, 2004
87. Vadam M, Furuya Y, Sakiyama J, et al. : NPS R-568 halts or reverses osteoitis fibrosis in uremic rats. Kidney Int 53 : 448 453, 1997
88. Fox J, Lowe SH, Conklin RL, Petty BA, Nemeth EF : Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2 +) receptor in rats. J Pharmacol Exp Ther 290 (2 480 486, 1999
89. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW : The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13 (4 1017 1024, 2002
90. Miller PD : Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 3 (1 5 12, 2005 Review
91. Stehman-Breen C : Osteoporosis and chronic kidney disease. Semin Nephrol 24 (1 78 81, 2004 Review
92. Weisinger JR, Bellorin-Font E : Postmenopausal osteoporosis in the dialysis patient. Curr Opin Nephrol Hypertens 12 (4 381 386, 2003 Review
93. Hernandez E, Valera R, Alonzo E, Bajares-Lilue M, Carlini R, Capriles F, Martinis R, Bellorin-Font E, Weisinger JR : Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 63 (6 2269 2274, 2003
94. Weisinger JR, Heilberg IP, Hernandez E, Carlini R, Bellorin-Font E : Selective estrogen receptor modulators in chronic renal failure. Kidney Int Suppl 85 : S62 S65, 2003 Review
95. Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, Sokalski A, Przedlacki J, Niemczyk S, Wlodarczyk D, Puka J, Switalski M : The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant 14 (5 1238 1243, 1999